PulseAugur
EN
LIVE 02:16:06
中文(ZH) 中信建投:一季度疫苗产品批签发同比增长,多款产品及新适应症获批

Vaccine batch releases up 14.1% in Q1 2026; smart glasses face privacy scrutiny

A recent report from CITIC Securities indicates a 14.1% year-over-year increase in vaccine batch releases during the first quarter of 2026, driven by significant growth in polio, measles-mumps-rubella, and hepatitis vaccines. The quarter also saw approvals for new indications and products, including vaccines from Chengda Bio, CanSino, and Kintor Pharma, with several other products under review. Separately, the burgeoning smart glasses industry is facing intense scrutiny over privacy concerns following an incident involving an airline attendant, prompting manufacturers to explore data handling and storage solutions to balance user experience with privacy protection. AI

IMPACT The discussion around smart glasses highlights the growing need for robust privacy mechanisms in AI-powered wearable technology.

RANK_REASON The item discusses industry trends and concerns rather than a specific new release or event.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Vaccine batch releases up 14.1% in Q1 2026; smart glasses face privacy scrutiny

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    CITIC Securities: First quarter vaccine product batch approvals increased year-on-year, multiple products and new indications approved

    36氪获悉,中信建投证券研报指出,2026年一季度疫苗行业整体批签发次数为875批次,同比增加14.1%,主要由于脊髓灰质炎疫苗、麻腮风疫苗、肝炎疫苗等产品签发批次大幅增长所致。研发方面,2026年一季度成大生物人二倍体狂苗、康希诺MCV4扩龄及组分百白破疫苗、康泰生物四价流感裂解疫苗等产品或新适应症获批;另有多款产品处于上市审评阶段。2026年疫苗行业应关注:1.创新疫苗管线后续研发节点及对外授权预期。2.产品销售改善,叠加新品上市贡献业绩增量。3.股权变更后续进展。